REGENT PACIFIC (00575.HK) announced that its commercial strategic partner Jiangsu Wanbang Pharmaceutical submitted a new drug application registration file to the National Medical Products Administration two days ago (17th) and is expected to receive approval within 12 months from the submission date.

Jiangsu Wanbang Pharmaceutical is responsible for obtaining new drug applications at its own expense from the National Medical Products Administration and maintaining any and all regulatory approvals required for importing Senstend in China. Additionally, it is important that Jiangsu Wanbang Pharmaceutical is fully responsible for the marketing, sales, and distribution of Senstend in China, and liaises with the manufacturer to procure and supply Senstend to achieve its sales targets.

Senstend is a proprietary formulation of two approved drugs, lidocaine and prilocaine, delivered through a metered aerosol spray developed for the treatment of premature ejaculation.